Vaccine breakthrough stops cancer returning in trial
North AmericaHealthHigh confidence — 91/100
A new personalised vaccine given in combination with a drug has stopped skin cancer returning in patients during a trial, representing a potentially watershed moment in cancer treatment.
The vaccine, developed by drug companies Merck and Moderna, was given to patients with high-risk melanoma, a type of skin cancer, after they had surgery.
Early results show this new jab extended the length of time these patients were cancer free, but it's unclear for how long, according to an announcement by the two firms.
Confirmed
The vaccine, developed by drug companies Merck and Moderna, was given to patients with high-risk melanoma, a type of skin cancer, after they had surgery.
Unverified
A new personalised vaccine given in combination with a drug has stopped skin cancer returning in patients during a trial, representing a potentially watershed moment in cancer treatment.
Early results show this new jab extended the length of time these patients were cancer free, but it's unclear for how long, according to an announcement by the two firms.